Yalniz, F. F. Et Al. 2017. Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors. TURKISH JOURNAL OF HEMATOLOGY , vol.34, no.3 , 233-238.

Yalniz, F. F., Akkoc, N., Salihoglu, A., Ar, M. C., Ongoren, S., Eskazan, A. E., ... Soysal, T.(2017). Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors. TURKISH JOURNAL OF HEMATOLOGY , vol.34, no.3, 233-238.

Yalniz, Fevzi Et Al. "Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors," TURKISH JOURNAL OF HEMATOLOGY , vol.34, no.3, 233-238, 2017

Yalniz, Fevzi F. Et Al. "Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors." TURKISH JOURNAL OF HEMATOLOGY , vol.34, no.3, pp.233-238, 2017

Yalniz, F. F. Et Al. (2017) . "Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors." TURKISH JOURNAL OF HEMATOLOGY , vol.34, no.3, pp.233-238.

@article{article, author={Fevzi Firat Yalniz Et Al. }, title={Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors}, journal={TURKISH JOURNAL OF HEMATOLOGY}, year=2017, pages={233-238} }